| Total | $50M |
| Series B, 7/09 New Enterprise Associates Kleiner Perkins Caufield & Byers The Column Group | $30M |
| Unattributed, 1/12 Kleiner Perkins Caufield & Byers New Enterprise Associates | $20M |
3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.
3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today.
